BR112016008254A2 - peptídeo tendo 4 epítopos de ctl ligados - Google Patents

peptídeo tendo 4 epítopos de ctl ligados

Info

Publication number
BR112016008254A2
BR112016008254A2 BR112016008254A BR112016008254A BR112016008254A2 BR 112016008254 A2 BR112016008254 A2 BR 112016008254A2 BR 112016008254 A BR112016008254 A BR 112016008254A BR 112016008254 A BR112016008254 A BR 112016008254A BR 112016008254 A2 BR112016008254 A2 BR 112016008254A2
Authority
BR
Brazil
Prior art keywords
peptide
ctl epitopes
epitope peptides
cancer
epitopes attached
Prior art date
Application number
BR112016008254A
Other languages
English (en)
Other versions
BR112016008254B1 (pt
Inventor
Wada Hiroshi
Fukaya Satoshi
Osada Toshihiro
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of BR112016008254A2 publication Critical patent/BR112016008254A2/pt
Publication of BR112016008254B1 publication Critical patent/BR112016008254B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

esta invenção refere-se a um peptídeo antigênico do câncer que pode ser administrado a uma faixa ampla de pacientes com câncer na forma de uma vacina de peptídeo para o câncer sem a necessidade de tipificação de hla e não obstante dos tipos de hla dos pacientes. tal peptídeo tendo 4 epítopos de clp ligados é obtido por ligação de 4 peptídeos de epítopo de ctl selecionados dentre peptídeos de epítopo de ctl derivados de moléculas de antígeno tumoral que são relatados como tendo a capacidade de indução de ctl por intermédio de ligantes.
BR112016008254-0A 2013-10-21 2014-10-20 Peptídeo que consiste em 4 epítopos de ctl ligados, composição de ctl, e composição farmacêutica BR112016008254B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2013218524 2013-10-21
JP2013-218524 2013-10-21
JP2014-155132 2014-07-30
JP2014155132 2014-07-30
PCT/JP2014/077807 WO2015060235A1 (ja) 2013-10-21 2014-10-20 新規ｃｔｌエピトープ４連結ペプチド

Publications (2)

Publication Number Publication Date
BR112016008254A2 true BR112016008254A2 (pt) 2017-09-26
BR112016008254B1 BR112016008254B1 (pt) 2023-05-30

Family

ID=

Also Published As

Publication number Publication date
EP3061771B1 (en) 2020-04-15
PL3061771T3 (pl) 2020-10-19
AU2014337643A1 (en) 2016-05-19
CN105658673B (zh) 2019-07-26
HUE050164T2 (hu) 2020-12-28
JP2017171678A (ja) 2017-09-28
EP3061771A1 (en) 2016-08-31
MX2016004754A (es) 2016-07-22
CA2927817C (en) 2019-02-26
JP6211093B2 (ja) 2017-10-11
AU2014337643B2 (en) 2017-07-13
CN105658673A (zh) 2016-06-08
KR101913333B1 (ko) 2018-10-30
WO2015060235A1 (ja) 2015-04-30
KR20160055922A (ko) 2016-05-18
RU2636549C1 (ru) 2017-11-23
DK3061771T3 (da) 2020-07-13
JPWO2015060235A1 (ja) 2017-03-09
PT3061771T (pt) 2020-05-06
US10137183B2 (en) 2018-11-27
TW201601749A (zh) 2016-01-16
US20160235828A1 (en) 2016-08-18
MY179119A (en) 2020-10-28
CA2927817A1 (en) 2015-04-30
PH12016500742A1 (en) 2016-06-20
SG11201603165TA (en) 2016-05-30
TWI651094B (zh) 2019-02-21
ES2796301T3 (es) 2020-11-26
PH12016500742B1 (en) 2016-06-20
EP3061771A4 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
CL2017001071A1 (es) Método para la cuantificación absoluta de péptidos cancerígenos hla-restringidos procesados naturalmente
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
BR112016015140A2 (pt) imunoglobulina com fabs in-tandem e usos das mesmas
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
MX2013002207A (es) Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
GT201200271A (es) Proteínas que se unen al tnf-a
BRPI0917315B8 (pt) anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo
BR112012018951B8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112014017862A2 (pt) epitopos modificados para aumento de respostas de célula t cd4+
ECSP13012913A (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
BR112018003877A2 (pt) “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”
BR112015004875A2 (pt) formulações de anticorpo e seus usos
BR112017012381A2 (pt) imunoterapia para doença angiogênica
BR112015008143A2 (pt) complexos, polipeptídeo e/ou polinucleotídeo isolado e purificado, composições, métodos para preparar, produzir ou obter complexos, para expandir e/ou desenvolver populações de células t autorreativas antipatogênicas e/ou para tratar esclerose múltipla ou distúrbio relacionado em sujeito com essa necessidade, kit e uso de complexos, de polipeptídeo e/ou de polinucleotídeo isolados e purificados e/ou de composições
PH12016500742B1 (en) Novel peptide having 4 linked ctl epitopes
BR112015031417A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
NZ594198A (en) Neil3 peptides and vaccines including the same
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
WO2012079878A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CL2019003422A1 (es) Nuevos péptidos (seq id n°171), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/10/2014, OBSERVADAS AS CONDICOES LEGAIS